314 related articles for article (PubMed ID: 9473755)
1. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
Walter AW; Shearer PD; Pappo AS; Greenwald CA; Rao BN; Bowman LC; Furman WL; Gajjar A; Jenkins JJ; Pratt CB
Med Pediatr Oncol; 1998 Apr; 30(4):210-6. PubMed ID: 9473755
[TBL] [Abstract][Full Text] [Related]
2. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
Bisogno G; Ferrari A; Bergeron C; Scagnellato A; Prete A; Alaggio R; Casanova M; D'Angelo P; Di Cataldo A; Carli M
Cancer; 2005 Apr; 103(8):1719-24. PubMed ID: 15754335
[TBL] [Abstract][Full Text] [Related]
3. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
4. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study.
Pratt CB; Maurer HM; Gieser P; Salzberg A; Rao BN; Parham D; Thomas PR; Marcus RB; Cantor A; Pick T; Green D; Neff J; Jenkins JJ
Med Pediatr Oncol; 1998 Apr; 30(4):201-9. PubMed ID: 9473754
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
9. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
[TBL] [Abstract][Full Text] [Related]
11. The value of adjuvant chemotherapy in the management of sarcomas in children.
Donaldson SS
Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
14. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
15. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Demetri GD; Elias AD
Hematol Oncol Clin North Am; 1995 Aug; 9(4):765-85. PubMed ID: 7490240
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
17. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
18. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
19. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Felgenhauer J; Hawkins D; Pendergrass T; Lindsley K; Conrad EU; Miser JS
Med Pediatr Oncol; 2000 Jan; 34(1):29-38. PubMed ID: 10611582
[TBL] [Abstract][Full Text] [Related]
20. Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Wang B; Yu X; Xu S; Xu M
Medicine (Baltimore); 2016 Jan; 95(4):e2611. PubMed ID: 26825914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]